How Did Australian Sales and a Wider Nutrition Portfolio Reshape Nuchev Limited (ASX:NUC) in FY26?

Aditi Sarkar

29 October 2026 05:09 PM AEDT

How Did Australian Sales and a Wider Nutrition Portfolio Reshape Nuchev Limited (ASX:NUC) in FY26?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

On 29 October 2026, Nuchev Limited (ASX:NUC) was quoted at AUD 0.080, with the daily change shown as unchanged. This article covers australian sales and geographic mix, gross profit and operating expenses and the company’s wider disclosures.
FY26 group revenue advanced 12.0% to AUD 25.7 million, with the Australian market supplying most sales growth.
Gross profit of AUD 11.2 million accompanied a lower 43.6% margin, while the adjusted EBITDA loss widened to AUD 4.6 million.

Nuchev Limited (ASX:NUC) has reported financial and commercial developments relevant to its FY26 and FY27 activities. On 29 October 2026, Nuchev Limited (ASX:NUC) was quoted at AUD 0.080, with the daily change shown as unchanged. FY26 group revenue advanced 12.0% to AUD 25.7 million, with the Australian market supplying most sales growth. Gross profit of AUD 11.2 million accompanied a lower 43.6% margin, while the adjusted EBITDA loss widened to AUD 4.6 million. The disclosures also address earnings and impairment and business priorities and distribution.

Australian Sales and Geographic Mix

Revenue in Australia rose 37.9% to AUD 19.4 million, compared with AUD 14.1 million in FY25. Domestic activity accounted for about 76% of total group sales. International revenue declined 29.3% to AUD 6.3 million, comprising AUD 4.9 million from China and AUD 1.4 million from Vietnam. The different geographic trends followed Nuchev’s efforts to broaden distribution of its nutrition and wellness portfolio. Management outlined the domestic expansion as a contributor to higher sales, while international activity remained uneven.

Gross Profit and Operating Expenses

Group gross profit increased 3.2% to AUD 11.2 million from AUD 10.9 million, even as sales rose at a faster rate. Gross margin declined by 3.7 percentage points to 43.6% from 47.3%, reflecting product and channel mix, promotional activity, product costs and logistics. Cost of sales reached AUD 14.5 million, compared with AUD 12.1 million. Employee benefits expense increased to AUD 7.4 million from AUD 6.1 million, and sales and marketing costs increased to AUD 4.5 million from AUD 4.2 million.

Earnings and Impairment

The adjusted EBITDA loss widened to AUD 4.6 million from AUD 3.3 million in FY25. Operating loss also increased to AUD 7.2 million from AUD 4.0 million. The group recorded a statutory loss after tax of approximately AUD 7.4 million, compared with AUD 3.8 million in the previous year. Its financial presentation identified a non-cash goodwill impairment of about AUD 1.9 million in the statutory outcome. Adjusted EBITDA is a company-defined non-IFRS measure and is separate from the statutory net result.

Cash Flow and Working Capital

Operating cash outflow totalled AUD 6.639 million in FY26, compared with AUD 3.742 million in FY25. The company reported AUD 5.267 million of financing inflows, including AUD 1.926 million from shares and AUD 3.500 million from borrowings, partly offset by lease repayments. Cash at 30 June 2026 was AUD 2.125 million, down from AUD 3.607 million one year earlier. The company connected the greater cash requirement with operating losses and investment in receivables and inventory as distribution broadened.

Business Priorities and Distribution

Nuchev described a wider nutrition and wellness platform with a particular focus on conversion, margin and cash. Domestic revenue expanded while international sales declined, creating a different regional balance from the previous year. Management highlighted channel and product mix, pricing, inventory and logistics as factors relevant to future operating performance. The FY26 result therefore contains both higher group revenue and lower margins, while funding and working-capital demands increased. Those disclosed factors form the company’s immediate operating agenda entering FY27.

Key Insights

Overall, Nuchev Limited reported fY26 group revenue advanced 12.0% to AUD 25.7 million, with the Australian market supplying most sales growth. gross profit of AUD 11.2 million accompanied a lower 43.6% margin, while the adjusted EBITDA loss widened to AUD 4.6 million. The announcement also addresses earnings and impairment, cash flow and working capital and business priorities and distribution. These are company-reported results and planned activities for their stated periods; announced targets, proposed transactions and pending approvals remain distinct from completed outcomes.

FAQs

Q: What was Nuchev’s FY26 revenue?

A: AUD 25.7 million, up 12.0% from FY25.

Q: How much revenue came from Australia?

A: AUD 19.4 million, representing approximately 76% of group revenue.

Q: What happened to the gross margin?

A: It declined from 47.3% to 43.6%.

Q: What was the adjusted EBITDA result?

A: An adjusted EBITDA loss of AUD 4.6 million.

Q: How much cash did Nuchev hold at year-end?

A: AUD 2.125 million at 30 June 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.